第一太平(00142.HK)聯營斥21億港元購雅加達收費公路40%權益
第一太平(00142.HK)公布,其菲律賓聯號公司MPIC間接控制約89.66%權益之附屬PT Margautama Nusantara,以作價4.03萬億印尼盾(約21億港元),收購PT Jasamarga Jalanlayang Cikampek(JCC)之40%股本權益。
JJC是雅加達-芝坎佩高架(Japex)收費公路之特許權持有人,Japex是全長38公里的全高架收費公路,構成跨爪哇網絡之一部分,貫通印尼首都雅加達與印尼之西爪哇、中爪哇及東爪哇各地。Japex自2019年12月12日起通車。Japex和Japex地面公路是雅加達最繁忙的收費公路之一,目前每天平均服務約44萬名駕駛者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.